Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NalmeCir: Nalmefene in Alcoholic Compensated Cirrhosis
NCT02824354Phase 3Withdrawn
- Sponsor
- CHU Amiens-Picardie
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alcohol dependence comparing Nalmefene with Placebo (2 arms). Primary endpoint: Reduction of the number of monthly heavy drinking days at 6 months. Planned start Dec 2018; status: withdrawn.
02
Drugs
nalmefene
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT02824354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824354.